Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones; Ended 2023 With Approximately $223M In Cash, Cash Equivalents And Marketable Securities, Which Is Anticipated To Fund Planned Operations Into Mid-2026

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!